From product launches and milestones, here are five updates in orthobiologics since March 28. 1. Lenoss Medical’s OsteoPearl procedure reached its 150th case. OsteoPearl is an allograft designed to augment vertebral compression fractures. 2. Spine Wave released its Tempest demineralized…
Biologics
CGBIO, a South Korea-based company, earned the FDA’s investigational device exemption approval for its Novosis putty for spinal fusions. The bone graft incorporates rhBMP-2 and is designed to enhance high-density bone formation and minimize ectopic bone growth, according to a…
A study reporting on DiscGenics’ cell therapy phase 1 and 2 study has been selected as one of three of the best and most influential articles published in the International Journal of Spine Surgery in 2024. Here are four things…
Ventris Medical earned FDA clearance to use its Backpack bone graft in intervertebral disc space. The bone graft earned its first FDA nod in January. Backpack is offered in two versions — one with Allocell AF allograft fibers and one…
Spine Wave released its Tempest demineralized cortical fibers in a full-market release. The launch marks the company’s push into the cortical fiber segment of the spinal allograft market, according to an April 9 news release. Tempest is made entirely of…
Advertisement
Lenoss Medical’s OsteoPearl procedure reached its 150th case, according to a March 27 news release shared with Becker’s. More than half of the 150 cases were completed since September. OsteoPearl is an allograft designed to augment vertebral compression fractures. It…
From new partnerships to product launches, here are 12 key developments in orthobiologics during the first quarter of 2025. 1. Medtronic and Kuros Biosciences signed a strategic agreement to support sales of the MagnetOs bone graft technology. Under the agreement…
Miach Orthopaedics' BEAR (bridge-enhanced ACL restoration) implant is now available to treat children and adolescents with anterior cruciate ligament tears after the FDA expanded its clearance.
Atreon Orthopedics earned expanded FDA 510(k) clearance for its Rotium bioreabsorbable wick, according to a March 6 news release.
Spine biologics is gaining more interest, and its innovation will be rooted in tailored patient care, Craig McMains, MD, said.